A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

NCT06788639 · tracked via the Priya Life Science USA tracker

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase

Observational

Started

2025-02-04

Last updated

2025-02-24

Condition(s) studied

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Investigational drug(s) / intervention(s)

Lisocabtagene maraleucel

Lisocabtagene maraleucel: According to the United States Prescribing Information

Study summary

The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: • Participants must have been treated in the post-marketing setting with ≥1 infusion of lisocabtagene maraleucel used for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within the approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA Exclusion Criteria: * Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion * Patients treated with non-conforming CAR T-cell product

Primary outcome measure(s)

Adverse events (AEs) — Up to 15 years

Trial sites (1)

Facility	City	Region	Status
Center for International Blood and Marrow Transplant Research (CIBMTR)	Milwaukee	Wisconsin	Recruiting

More Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trials in the USA

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) Active, not recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma Recruiting

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) Recruiting

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) Starting soon

Other trials for the same condition

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab Recruiting

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Active, not recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06788639 on ClinicalTrials.gov ↗ ← All trials in the USA